课题基金 / 基金详情

Stem cell-derived Encapsulated Liver Tissue to treat liver failure without immunosuppression: technology maturation towards clinical translation

Stem cell-derived Encapsulated Liver Tissue to treat liver failure without immunosuppression: technology maturation towards clinical translation
干细胞衍生的包封肝组织无需免疫抑制即可治疗肝衰竭：技术成熟走向临床转化
批准号：
391206
负责人：
Paganelli Massimiliano
金额：
$36.22万
依托单位：
Centre hospitalier universitaire Sainte-Justine (Montral, Qubec)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2018
资助国家：
加拿大
项目状态：
已结题
起止时间：
2018-09-01 至 2021-09-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=391206&lang=en
关键词：
Commercialization Liver Failure Liver Organoids Product Development Regenerative Medicine Stem Cell-Derived Tissues Technology Transfer

项目摘要

项目成果

Paganelli Massimiliano的其他基金

相似基金

相关文献

中文摘要
翻译
肝功能衰竭是大多数进展性肝病的常见后果。急性肝功能衰竭患者需要在确诊后几天内接受肝脏移植，以免他们的疾病变得不可逆转地过于严重。我们开发了一种植入型
英文摘要
Liver failure is the common outcome of most progressive liver diseases. Patients with acute liver failure need to receive a liver transplant within days from the diagnosis, before their disease becomes irreversibly too severe. We developed an implantable
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Heterologous stem cell therapy to treat acute liver failure in infants, children and adolescents without the need of immunosuppression
海外基金